Valor Management LLC Invests $19.84 Million in BrainsWay Ltd. (NASDAQ:BWAY)

Valor Management LLC purchased a new stake in shares of BrainsWay Ltd. (NASDAQ:BWAY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,103,745 shares of the company's stock, valued at approximately $19,838,000. BrainsWay makes up approximately 8.0% of Valor Management LLC's holdings, making the stock its 2nd largest holding. Valor Management LLC owned about 11.18% of BrainsWay at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of BWAY. Phoenix Financial Ltd. boosted its stake in shares of BrainsWay by 100.8% in the fourth quarter. Phoenix Financial Ltd. now owns 482,724 shares of the company's stock valued at $4,552,000 after purchasing an additional 242,366 shares during the period. ARK Investment Management LLC bought a new stake in BrainsWay in the fourth quarter valued at about $1,656,000. MYDA Advisors LLC lifted its stake in BrainsWay by 100.2% during the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company's stock worth $1,133,000 after purchasing an additional 60,100 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of BrainsWay by 2.0% in the 4th quarter. Two Sigma Investments LP now owns 92,755 shares of the company's stock worth $875,000 after buying an additional 1,786 shares during the last quarter. Finally, Zuckerman Investment Group LLC lifted its holdings in BrainsWay by 346.4% in the fourth quarter. Zuckerman Investment Group LLC now owns 67,000 shares of the company's stock worth $667,000 after acquiring an additional 51,991 shares during the last quarter. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

BrainsWay Stock Performance

Shares of NASDAQ:BWAY opened at $10.65 on Tuesday. BrainsWay Ltd. has a one year low of $5.13 and a one year high of $11.79. The company has a market capitalization of $200.99 million, a PE ratio of 106.51 and a beta of 1.25. The stock has a fifty day moving average of $9.14 and a 200-day moving average of $9.71.

BrainsWay (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. The business had revenue of $11.54 million during the quarter, compared to the consensus estimate of $11.45 million. As a group, research analysts forecast that BrainsWay Ltd. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of BrainsWay in a research report on Wednesday, March 12th.

BrainsWay Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BrainsWay Ltd. (NASDAQ:BWAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.